{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:33:49Z","timestamp":1789526029236,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3268-5","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T09:15:06Z","timestamp":1533028506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)"],"prefix":"10.1186","volume":"18","author":[{"name":"on behalf of CISAI Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-6358","authenticated-orcid":false,"given":"Lucia","family":"Taramasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tatarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Menzaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Squillace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canio","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gulminetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Orofino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"3268_CR1","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1086\/518285","volume":"44","author":"N Obel","year":"2007","unstructured":"Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, S\u00f8rensen HT, Gerstoft J. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44:1625\u201331.","journal-title":"Clin Infect Dis"},{"key":"3268_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1086\/375844","volume":"37","author":"M Sav\u00e8s","year":"2003","unstructured":"Sav\u00e8s M, Ch\u00eane G, Ducimeti\u00e8re P, Leport C, Le Moal G, Amouyel P, Arveiler D, Ruidavets JB, Reynes J, Bingham A, Raffi F. French WHO MONICA project and the APROCO (ANRS EP11) study group, Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003;37:292\u20138.","journal-title":"Clin Infect Dis"},{"key":"3268_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s15010-016-0893-z","volume":"44","author":"GV De Socio","year":"2016","unstructured":"De Socio GV, Ricci E, Parruti G, Calza L, Maggi P, Celesia BM, Orofino G, Madeddu G, Martinelli C, Menzaghi B, Taramasso L, Penco G, Carenzi L, Franzetti M, Bonfanti P. Statins and aspirin use in HIV-infected people: gap between European AIDS clinical society guidelines and clinical practice: the results from HIV-HY study. Infection. 2016;44:589\u201397.","journal-title":"Infection"},{"key":"3268_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ecl.2014.06.003","volume":"43","author":"T Kelesidis","year":"2014","unstructured":"Kelesidis T, Currier JS. Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection. Endocrinol Metab Clin N Am. 2014;43:665\u201384.","journal-title":"Endocrinol Metab Clin N Am"},{"key":"3268_CR5","doi-asserted-by":"publisher","first-page":"ofx239","DOI":"10.1093\/ofid\/ofx239","volume":"4","author":"L Taramasso","year":"2017","unstructured":"Taramasso L, Ricci E, Menzaghi B, Orofino G, Passerini S, Madeddu G, Martinelli CV, De Socio GV, Squillace N, Rusconi S, Bonfanti P, Di Biagio A, CISAI Study Group. Weight gain: a possible side effect of all antiretrovirals. Open Forum Infect Dis. 2017;4:ofx239.","journal-title":"Open Forum Infect Dis"},{"key":"3268_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/cid\/civ296","volume":"61","author":"JR Santos","year":"2015","unstructured":"Santos JR, Saumoy M, Curran A, Bravo I, Llibre JM, Navarro J, Estany C, Podzamczer D, Ribera E, Negredo E, Clotet B, Paredes R. Tenofovir\/emtricitabine inflUence on LIPid metabolism (TULIP) study group, The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, douARTe-blind, placebo-controlled trial. Clin Infect Dis. 2015;61:403\u20138.","journal-title":"Clin Infect Dis"},{"key":"3268_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/jac\/dkq507","volume":"66","author":"P Maggi","year":"2011","unstructured":"Maggi P, Bellacosa C, Carito V, Perilli F, Lillo A, Volpe A, Trillo G, Angiletta D, Regina G, Angarano G. Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens. J Antimicrob Chemother. 2011;66:896\u2013900.","journal-title":"J Antimicrob Chemother"},{"key":"3268_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","volume":"378","author":"JM Molina","year":"2011","unstructured":"Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K, ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238\u201346.","journal-title":"Lancet"},{"key":"3268_CR9","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1086\/381783","volume":"189","author":"E Fontas","year":"2004","unstructured":"Fontas E, van Leth F, Sabin CA, Friis-M\u00f8ller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P, D:A:D study group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056\u201374.","journal-title":"J Infect Dis"},{"key":"3268_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/cid\/cir510","volume":"53","author":"JK Rockstroh","year":"2011","unstructured":"Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, Walker ML, Xu X, Zhao J, Teppler H, Dinubile MJ, Rodgers AJ, Nguyen BY, Leavitt R, Sklar P, STARTMRK investigators. Long-term treatment with raltegravir or efavirenz combined with tenofovir\/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53:807\u201316.","journal-title":"Clin Infect Dis"},{"key":"3268_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","volume":"381","author":"F Raffi","year":"2013","unstructured":"Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S, SPRING-2 study group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735\u201343.","journal-title":"Lancet"},{"key":"3268_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/01.qai.0000164248.56722.3c","volume":"39","author":"P Bonfanti","year":"2005","unstructured":"Bonfanti P, Martinelli C, Ricci E, Carradori S, Parruti G, Armignacco O, Magnani C, Quirino T, CISAI group (Italian coordinators for the study of allergies HIV infection). An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (surveillance cohort long-term toxicity Antiretrovirals) project on the safety of lopinavir\/ritonavir. J Acquir Immune Defic Syndr. 2005;39:317\u201320.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3268_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D'Agostino Sr","year":"2008","unstructured":"D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117:743\u201353.","journal-title":"Circulation"},{"key":"3268_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12879-017-2510-x","volume":"17","author":"GV De Socio","year":"2017","unstructured":"De Socio GV, Pucci G, Baldelli F, Schillaci G. Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study. BMC Infect Dis. 2017;17:414.","journal-title":"BMC Infect Dis"},{"key":"3268_CR15","unstructured":"European AIDS Clinical Society (EACS) Guidelines. Version 9.0. October 2017. Available at \n                    http:\/\/www.eacsociety.org\/files\/guidelines_9.0-english.pdf\n                    \n                  . Accessed 30 Nov 2017."},{"key":"3268_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/QAD.0000000000000087","volume":"28","author":"FJ Palella Jr","year":"2014","unstructured":"Palella FJ Jr, Fisher M, Tebas P, Gazzard B, Ruane P, Van Lunzen J, Shamblaw D, Flamm J, Ebrahimi R, Porter D, White K, Hindman J, Elbert E, De-Oertel S, Fralich T. Simplification to rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28:335\u201344.","journal-title":"AIDS"},{"key":"3268_CR17","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1097\/QAI.0000000000000727","volume":"70","author":"C Pinnetti","year":"2015","unstructured":"Pinnetti C, Di Giambenedetto S, Maggiolo F, Fabbiani M, Sterrantino G, Latini A, Lorenzini P, Ammassari A, Loiacono L, Bellagamba R, Boumis E, Cauda R, Antinori A, Zaccarelli M. Switching to Coformulated Rilpivirine\/Emtricitabine\/Tenofovir in Virologically suppressed patients: data from a multicenter cohort. J Acquir Immune Defic Syndr. 2015;70:e147\u201350.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3268_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ijantimicag.2016.07.009","volume":"48","author":"A Di Biagio","year":"2016","unstructured":"Di Biagio A, Riccardi N, Taramasso L, Capetti A, Cenderello G, Signori A, Vitiello P, Guerra M, De Socio GV, Cassola G, Quirino T, Viscoli C. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides. Int J Antimicrob Agents. 2016;48:551\u20134.","journal-title":"Int J Antimicrob Agents"},{"key":"3268_CR19","volume-title":"3-year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz\/emtricitabine\/tenofovir and rilpivirine\/emtricitabine\/tenofovir, Antivir Ther","author":"R Gagliardini","year":"2017","unstructured":"R Gagliardini, A Bandera, M Zaccarelli, G Sterrantino, A Latini, A D'Avino, G Lapadula, A Antinori, R Cauda, A De Luca, A Gori, S Di Giambenedetto, M Fabbiani, 3-year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz\/emtricitabine\/tenofovir and rilpivirine\/emtricitabine\/tenofovir, Antivir Ther. 2017 [Epub ahead of print]."},{"key":"3268_CR20","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1097\/QAD.0000000000001675","volume":"31","author":"JM Gatell","year":"2017","unstructured":"Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL, NEAT022 Study Group. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 2017;31:2503\u201314.","journal-title":"AIDS"},{"key":"3268_CR21","first-page":"844","volume":"72","author":"E Negredo","year":"2017","unstructured":"Negredo E, Estrada V, Domingo P, Guti\u00e9rrez MD, Mateo GM, Puig J, Bonjoch A, Ornelas A, Echeverr\u00eda P, Estany C, Toro J, Clotet B. Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. J Antimicrob Chemother. 2017;72:844\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"3268_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3851\/IMP3166","volume":"22","author":"B Trottier","year":"2017","unstructured":"Trottier B, Lake JE, Logue K, Brinson C, Santiago L, Brennan C, Koteff JA, Wynne B, Hopking J, Granier C, Aboud M. Dolutegravir\/abacavir\/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther. 2017;22:295\u2013305.","journal-title":"Antivir Ther"},{"key":"3268_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/15284336.2017.1330440","volume":"18","author":"JR Arribas","year":"2017","unstructured":"Arribas JR, DeJesus E, van Lunzen J, Zurawski C, Doroana M, Towner W, Lazzarin A, Nelson M, McColl D, Andreatta K, Swamy R, Szwarcberg J, Nguyen T. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. HIV Clin Trials. 2017;18:118\u201325.","journal-title":"HIV Clin Trials."},{"key":"3268_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/15284336.2017.1338844","volume":"18","author":"A Pozniak","year":"2017","unstructured":"Pozniak A, Flamm J, Antinori A, Bloch M, Ward D, Berenguer J, Cote P, Andreatta K, Garner W, Szwarcberg J, Nguyen-Cleary T, McColl DJ, Piontkowsky D. Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-NNRTI. HIV Clin Trials. 2017;18:141\u20138.","journal-title":"HIV Clin Trials"},{"key":"3268_CR25","doi-asserted-by":"publisher","first-page":"802","DOI":"10.7326\/0003-4819-139-10-200311180-00007","volume":"139","author":"T McLaughlin","year":"2003","unstructured":"McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802\u20139.","journal-title":"Ann Intern Med"},{"key":"3268_CR26","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.amjcard.2012.02.016","volume":"109","author":"MR Salazar","year":"2012","unstructured":"Salazar MR, Carbajal HA, Espeche WG, Leiva Sisnieguez CE, Balb\u00edn E, Dulbecco CA, Aizpur\u00faa M, Marillet AG, Reaven GM. Relation among the plasma triglyceride\/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. Am J Cardiol. 2012;109:1749\u201353.","journal-title":"Am J Cardiol"},{"key":"3268_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.beem.2010.12.001","volume":"25","author":"M Giralt","year":"2011","unstructured":"Giralt M, Domingo P, Villarroya F. Adipose tissue biology and HIV-infection. Best Pract Res Clin Endocrinol Metab. 2011;25:487\u201399.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"3268_CR28","unstructured":"Department of Health and Human Services (DHHS). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available at \n                    https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf\n                    \n                  . Accessed 11 June 2018."},{"key":"3268_CR29","unstructured":"Societ\u00e0 Italiana di Maalttie Infettive e Tropicali (SIMIT): Linee Guida Italiane sull\u2019utilizzo della Terapia Antiretrovirale e la gestione diagnostico-clinica delle persone con infezione da HIV-1. Available at \n                    http:\/\/www.simit.org\/medias\/1257-l-g-hiv-simit-2017.pdf\n                    \n                  . Accessed 11 Jun 2018."},{"key":"3268_CR30","first-page":"86","volume":"40","author":"A Antinori","year":"2017","unstructured":"Antinori A, Di Biagio A, Marcotullio S, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. New Microbiol. 2017;40:86\u201398.","journal-title":"New Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3268-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3268-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3268-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T19:07:14Z","timestamp":1564513634000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3268-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3268"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3268-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"assertion":[{"value":"11 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol of the SCOLTA Group was approved by local ethical committees (Comitato Etico Regione Liguria, Ospedale Policlinico San Martino, Italy; Comitato Etico dell\u2019Azienda Ospedaliero- Universitaria di Sassari, Italy; Comitato Etico ASST Valle Olona, c\/o Azienda Ospedaliera \u201cOspedale di Circolo e Fondazione Macchi di Varese\u201d; Comitato Etico, Universit\u00e0 degli Studi Milano-Bicocca, Monza, Italy; Comitato Etico delle Aziende Sanitarie dell\u2019Umbria (CEAS Umbria), Ellera di Corciano (Perugia), Italy; Comitato Etico di Area Vasta Centro, Oepdale Careggi, Firenze, Italy; Comitato Etico IRCCS San Matteo, Pavia, Italy; Comitato Etico Interregionale, Policlinico di Bari, Italy; Comitato Etico Interaziendale A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Italy; Comitato Etico Azienda Socio Sanitaria Territoriale ASST Lecco, Italy) and conducted in accordance with the ethical principles stated in the Declaration of Helsinki. Written consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"357"}}